Literature DB >> 1175506

Effects of the octapeptide of cholecystokinin on insulin and glucagon secretion in the dog.

C M Frame, M B Davidson, R A Sturdevant.   

Abstract

The effects of intravenous infusion of synthetic C-terminal octapeptide of cholecystokinin (OP-CCK) on concentrations of insulin and glucagon in peripheral venous plasma of conscious dogs were studied. Both hormones increased in response to 160 and 480 ng/kg/h of OP-CCK. The increases to 480 ng/kg/h were larger than those to 160 ng/kg/h. Peripheral venous concentrations of glucose and intestinal glucagon-like immunoreactivity were not altered by OP-CCK. OP-CCK, 160 ng/kg/h, did not enhance insulin and glucagon responses to intravenous infusion of amino acids. The results suggest that insulin- and glucagon-releasing actions of porcine cholecystokinin preparations should not be attributed entirely to gastric inhibtory polypeptide or other impurities contained in these preparations since the synthetic active fragment of cholecystokinin alone increases insulin and and glucagon concentrations in peripheral plasma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1175506     DOI: 10.1210/endo-97-3-549

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  The enteral insulin-stimulation after Whipple's operation.

Authors:  J F Rehfeld; F Stadil; H Baden; K Fischerman
Journal:  Diabetologia       Date:  1975-06       Impact factor: 10.122

2.  The effects of gastrin, gastric inhibitory polypeptide, secretin, and the octapeptide of cholecystokinin upon immunoreactive somatostatin release by the perfused canine pancreas.

Authors:  E Ipp; R E Dobbs; V Harris; A Arimura; W Vale; R H Unger
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  The effects of structural modifications on the insulin-releasing activity of beta-cell-tropin.

Authors:  S J Dunmore; M Panico; A T Etienne; H R Morris; A Beloff-Chain
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

4.  Discrepancies between the doses of cholecystokinin or caerulein-stimulating exocrine and endocrine responses in perfused isolated rat pancreas.

Authors:  M Otsuki; C Sakamoto; H Yuu; M Maeda; S Morita; A Ohki; N Kobayashi; K Terashi; K Okano; S Baba
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

5.  Insulin and myoelectric activity of the small intestine of the pig.

Authors:  V Rayner; T E Weekes; J B Bruce
Journal:  Dig Dis Sci       Date:  1981-01       Impact factor: 3.199

6.  Effects of two cholecystokinin variants, CCK-39 and CCK-8, on basal and stimulated insulin secretion.

Authors:  B Ahrén; I Lundquist
Journal:  Acta Diabetol Lat       Date:  1981 Oct-Dec

7.  L-364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs.

Authors:  R Hosotani; P Chowdhury; P L Rayford
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

8.  Energy homeostasis in apolipoprotein AIV and cholecystokinin-deficient mice.

Authors:  Jonathan Weng; Danwen Lou; Stephen C Benoit; Natalie Coschigano; Stephen C Woods; Patrick Tso; Chunmin C Lo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-08-02       Impact factor: 3.619

9.  Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice.

Authors:  Chun-Min Lo; Silvana Obici; H Henry Dong; Michael Haas; Dawnwen Lou; Dae Hyun Kim; Min Liu; David D'Alessio; Stephen C Woods; Patrick Tso
Journal:  Diabetes       Date:  2011-05-20       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.